ANO1 protein as a potential biomarker for esophageal cancer prognosis and precancerous lesion development prediction

• Published in: Oncotarget Vol. 7; no. 17; pp. 24374 - 24382
• Main Authors: Shang, Li, Hao, Jia-Jie, Zhao, Xue-Ke, He, Jian-Zhong, Shi, Zhi-Zhou, Liu, Hui-Juan, Wu, Li-Fei, Jiang, Yan-Yi, Shi, Feng, Yang, Hai, Zhang, Yu, Liu, Yi-Zhen, Zhang, Tong-Tong, Xu, Xin, Cai, Yan, Jia, Xue-Mei, Li, Min, Zhan, Qi-Min, Li, En-Min, Wang, Li-Dong, Wei, Wen-Qiang, Wang, Ming-Rong
• Format: Journal Article
• Language: English
• Published: United States 26.04.2016
• Subjects: Anoctamin-1 - biosynthesis; Biomarkers, Tumor - metabolism; Carcinoma, Squamous Cell - diagnosis; Carcinoma, Squamous Cell - metabolism; Disease Progression; Esophageal Neoplasms - diagnosis; Esophageal Neoplasms - metabolism; Esophagus - metabolism; Esophagus - pathology; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Proteins - biosynthesis; Precancerous Conditions - diagnosis; Precancerous Conditions - metabolism; Prognosis; ANO1; esophageal squamous cell carcinoma; biomarker; prognosis; precancerous lesions
• DOI: 10.18632/oncotarget.8223

Anoctamin 1 (ANO1) has been found to be overexpressed in esophageal squamous cell carcinoma (ESCC) in our previous study. Herein we showed the clinical relevance of ANO1 alterations with ESCC and esophageal precancerous lesion progression. ANO1 was detected in 38.1% (109/286) and 25.4% (77/303) of tumors in the two cohorts, but in none of morphologically normal operative margin tissues. ANO1 expression was significantly associated with a shorter overall survival (OS), especially in patients with moderately differentiated and stage IIA tumors. In 499 iodine-unstained biopsies from the endoscopic screening cohort in 2005-2007, all the 72 pathologically normal epithelial mucosa presented negative immunostaining, whereas ANO1 expression was observed in 3/11 tumors and 5/231 intraepithelial lesions. 7/8 ANO1-positive cases had developed unfavorable outcomes revealed by endoscopic follow-up in 2012. Analysis of another independent cohort of 148 intraepithelial lesions further confirmed the correlation between ANO1 expression and progression of precancerous lesions. 3/4 intraepithelial lesions with ANO1 expression had developed ESCC within 4-9 years after the initial endoscopic examination. Immunohistochemistry (IHC) was performed to examine ANO1 expression in surgical ESCC specimens and two independent cohorts of esophageal biopsies from endoscopic screening in high-incidence area of ESCC in northern China. Association between ANO1 expression, clinico-pathologic parameters, and the impact on overall survival was analyzed. Positive ANO1 is a promising biomarker to predict the unfavorable outcome for ESCC patients. More importantly, it can predict disease progression of precancerous lesions.